Toll-Like Receptor 3 as a Recurrence Risk Factor and a Potential Molecular Therapeutic Target in Colorectal Cancer

Area of Science:

• Oncology
• Immunology

Background:

• Colorectal cancer (CRC) recurrence post-curative resection necessitates identification of key risk factors.
• The role of Toll-like receptor 3 (TLR3) in CRC development and recurrence remains incompletely understood.

Purpose of the Study:

• To investigate the association between TLR3 expression and clinicopathological factors, prognosis, and recurrence in colorectal cancer patients.
• To explore the relationship between TLR3 and chemokine expression in CRC.

Main Methods:

• Immunohistochemistry was used to assess TLR3 expression in 50 colorectal cancer samples.
• Correlations between TLR3 status, clinicopathological variables, and recurrence-free survival (RFS) were analyzed.
• Chemokine induction by TLR3 agonist stimulation was studied in CRC cell lines.

Main Results:

• TLR3-negative status was significantly associated with lymph node metastasis.
• Patients with TLR3-negative tumors exhibited a significantly lower 5-year recurrence-free survival (46.2%) compared to TLR3-positive tumors (78.1%).
• High tumor budding and TLR3-negative status were identified as independent risk factors for CRC recurrence. TLR3 activation induced CCL2, CCL5, and IL-8 expression in CRC cell lines.

Conclusions:

• Non-expression of TLR3 in colorectal cancer cells is linked to lymph node metastasis and serves as an independent risk factor for recurrence.
• TLR3 status holds potential as a prognostic and predictive factor for colorectal cancer recurrence.
• Further research into TLR3's role in tumor growth could unveil novel therapeutic avenues for colorectal cancer.